{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:17:54Z","timestamp":1788358674966,"version":"build-2803163510"},"reference-count":28,"publisher":"Baishideng Publishing Group Inc.","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastroenterol"],"abstract":"BACKGROUND<\/jats:p>\n The efficacy and safety profile of tenofovir amibufenamide (TMF) in chronic hepatitis B (CHB) patients is not well-established.<\/jats:p>\n AIM<\/jats:p>\n To compare the efficacy and safety of TMF and tenofovir alafenamide (TAF) over a 48-wk period in patients with CHB.<\/jats:p>\n METHODS<\/jats:p>\n A total of 215 subjects meeting the inclusion criteria were enrolled and divided into two groups: TMF group (n = 106) and the TAF group (n = 109). The study included a comparison of virological response (VR): Undetectable hepatitis B virus DNA levels, alanine transaminase (ALT) normalization rates, renal function parameters, and blood lipid profiles.<\/jats:p>\n RESULTS<\/jats:p>\n At 24 and 48 wk, VR rates for the TMF group were 53.57% and 78.57%, respectively, compared with 48.31% and 78.65% for the TAF group (P > 0.05). The VR rates were also similar in both groups among patients with low-level viremia, both hepatitis B e antigen (HBeAg)-positive and HBeAg-negative subgroups. The TMF cohort showed ALT normalization and renal safety profiles similar to the TAF group. There was a notable increase in total cholesterol levels in the TAF group (P = 0.045), which was not observed in the TMF group (P > 0.05). In patients with liver cirrhosis, both groups exhibited comparable VR and ALT normalization rates and renal safety profiles. However, the fibrosis 4 score at 48 wk showed a significant reduction in the TAF group as compared to the TMF group within the liver cirrhosis subgroup.<\/jats:p>\n CONCLUSION<\/jats:p>\n Our study found TMF is as effective as TAF in treating CHB and has a comparable safety profile. However, TAF may be associated with worsening lipid profiles.<\/jats:p>","DOI":"10.3748\/wjg.v29.i44.5907","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T05:24:32Z","timestamp":1701062672000},"page":"5907-5918","source":"Crossref","is-referenced-by-count":21,"title":["Tenofovir amibufenamide vs<\/i> tenofovir alafenamide for treating chronic hepatitis B: A real-world study"],"prefix":"10.3748","volume":"29","author":[{"given":"Wen-Ting","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Lan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian-Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Fang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"B1","unstructured":"Hepatitis B Fact Sheet. World Health Organization. 2021. Available from: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033364"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.032"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-15"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20220209-00060"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00734"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.932934"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16611"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00058"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104614"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00184"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16196"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.009"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14497"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001466"},{"key":"B22","unstructured":"Administration UF, D. , Prescribing information for vemlidy (tenofovir alafenamide) 2016."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2014.909724"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0236"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12664"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1165990"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0145-y"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v29\/i44\/5907.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v29\/i44\/5907.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T05:24:49Z","timestamp":1701062689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v29\/i44\/5907.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":28,"journal-issue":{"issue":"44"},"URL":"https:\/\/doi.org\/10.3748\/wjg.v29.i44.5907","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}